Combining precision medicine and prophylaxis in oesophageal squamous cell carcinoma

Mark A Baxter; Lindsay C Spender; Russell D Petty

doi:10.1038/s41416-020-01057-3

Combining precision medicine and prophylaxis in oesophageal squamous cell carcinoma

Br J Cancer. 2020 Nov;123(11):1585-1587. doi: 10.1038/s41416-020-01057-3. Epub 2020 Sep 22.

Authors

Mark A Baxter^{1

2}, Lindsay C Spender¹, Russell D Petty^{3

4}

Affiliations

¹ Medical Oncology, Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, UK.
² Tayside Cancer Centre, Ninewells Hospital and Medical School, NHS Tayside, Dundee, Scotland, UK.
³ Medical Oncology, Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, UK. r.petty@dundee.ac.uk.
⁴ Tayside Cancer Centre, Ninewells Hospital and Medical School, NHS Tayside, Dundee, Scotland, UK. r.petty@dundee.ac.uk.

Abstract

A trial update confirms improved survival for prophylactic elective nodal irradiation and addition of erlotinib to definitive chemoradiotherapy in oesophageal squamous cell carcinoma (ESCC). High tumour EGFR protein expression shows promise to identify those who will benefit from erlotinib. This represents therapeutic progress, and has wider relevance for precision medicine strategies in ESCC.

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Carcinoma, Squamous Cell* / drug therapy
Chemoradiotherapy
Erlotinib Hydrochloride / therapeutic use
Esophageal Neoplasms* / drug therapy
Esophageal Squamous Cell Carcinoma* / therapy
Head and Neck Neoplasms*
Humans
Precision Medicine

Substances

Erlotinib Hydrochloride

Abstract

Publication types

MeSH terms

Substances

Grants and funding